Introduction {#sec0005}
============

Age-related macular degeneration (AMD) is a major cause of visual impairment in people over 50 years of age and the commonest cause of blindness in Western populations ([@bib0060]). It affects the macula, the region of the retina rich in photoreceptors which provides detailed central vision. In the early stages of the disease (age-related maculopathy, ARM), deposits called drusen form between the retinal pigment epithelium (RPE) and underlying choroid. Later in the disease there is atrophy of the RPE and overlying photoreceptor cells (geographic atrophy, GA) and/or aberrant choroidal neovascularisation (CNV, also called wet AMD) ([@bib0060]). Susceptibility to AMD is influenced by age, ethnic background, genetic and environmental factors, particularly smoking ([@bib0060; @bib0125]).

Common variants in a number of genes have been shown to influence the risk of developing AMD ([@bib0125]), including complement factor H (CFH) ([@bib0085; @bib0045; @bib0030; @bib0055]), complement factor B (CFB) and/or complement 2 (C2) ([@bib0040]), complement 3 (C3) ([@bib0145]) and complement factor I (CFI) ([@bib0035]). The involvement of genes in the complement pathway, particularly complement regulators, together with the finding that drusen contain proteins associated with inflammation and immune-mediated processes ([@bib0095; @bib0005]) supports the hypothesis that complement activation is important in the pathogenesis of AMD. We have investigated variants in the major genes encoding proteins in the alternative complement pathway for evidence of association with AMD and the results for CFH, CFB, CFI, C3 and C5 have been reported elsewhere ([@bib0120; @bib0145; @bib0155]). Because complement activation appears to be central to the pathogenesis of AMD, we have studied other regulators of the alternative complement pathway and the results are presented here.

Materials and methods {#sec0010}
=====================

Patients and controls {#sec0015}
---------------------

The sample comprised cases with predominantly advanced AMD (GA or CNV) and spouse controls recruited from hospital ophthalmic clinics in London and the South East of England. All subjects described themselves as "white" on a recruitment questionnaire. The study had Research Ethics Committee approval and written consent was obtained from all participants. Subjects were examined by an ophthalmologist and health, lifestyle and smoking data were collected. All subjects had colour, stereoscopic fundus photography of the macular region. These images were independently graded at the Reading Centre, Moorfields Eye Hospital, London using the International Classification of Age-related Maculopathy and Macular Degeneration ([@bib0015]).

SNP selection and genotyping {#sec0020}
----------------------------

Genomic DNA was extracted from peripheral blood leucocytes and typed for variants spanning the genes encoding complement factor P (CFP, properdin), CD46 (membrane cofactor protein, MCP), CD55 (decay accelerating factor, DAF) and CD59 (protectin). SNPs were selected from the International HapMap Project ([@bib0135]) database (release 19) for the CEPH population (Utah residents with ancestry from northern and western Europe). In an initial round of genotyping, SNPs with a minor allele frequency of at least 10% were selected to cover the main blocks of linkage disequilibrium. Subsequently, genetic coverage of the four genes of interest was formally calculated using the Tagger tag SNP selection algorithm ([@bib0025]) implemented in Haploview v4.1 ([@bib0010]) and reported as percentage number of CEPH HapMap SNPs (genotype rate ≥ 90%; minor allele frequency (MAF) ≥ 1%; Hardy--Weinberg equilibrium (HWE) *p*-value ≥ 10^−4^; maximum number of Mendelian errors = 1) captured by (at least) one genotyped SNP (at *r*^2^ ≥ 0.80). On the basis of this analysis, additional genotyping was carried out and the final coverage achieved was 83% for CFP, 71% for CD46, 92% for CD55 and 71% for CD59. SNPs were genotyped using the ABI PRISM SNaPshot ddNTP Primer Extension Kit and a 3100 Genetic Analyser (Applied Biosystems) with the exception of rs7060246 which was typed using Taqman (Applied Biosystems). Manufacturers' protocols were followed.

Statistical analysis {#sec0025}
--------------------

Differences in the demographic characteristics of cases and controls were assessed using the Fisher\'s Exact test for categorical variables and the two sample Mann--Whitney test for continuous variables as implemented in STATA (Version 11.1, StataCorp LP, College Station, TX). A difference was considered significant if the *p*-value was found to be less than 0.05. Genetic association analysis was conducted using PLINK v1.07 ([@bib0100]). Departure from HWE was assessed in controls. SNP association analysis was performed using the Cochran--Armitage trend test and corresponding *p*-values are reported. Odds ratios (ORs) were calculated using referent minor allele and are presented with 95% confidence intervals (CIs). We performed logistic regression analyses adjusting for age and pack years of cigarette smoking to address the possibility that SNP genotypes were confounded by these demographic factors.

Results {#sec0030}
=======

20 SNPs spanning the four genes of interest were genotyped in 446 cases and 262 controls. For two SNPs with *p*-values approaching statistical significance, additional subjects were genotyped to increase the numbers to 622 cases and 359 controls. Data on disease status, sex, age and smoking history of subjects are given in [Table 1](#tbl0005){ref-type="table"}. The SNPs that were typed in each gene are listed in [Table 2](#tbl0010){ref-type="table"} together with the results of genotyping and tests for association. For all SNPs no departure from HWE was observed in control samples. There was no evidence of association between AMD and any of the SNPs in CFP, CD46, CD55 and CD59. Adjusting the analysis for age and pack years of cigarette smoking, excluding cases with ARM or confining the analysis to cases with either CNV or GA did not significantly alter the estimates (results not shown).

Discussion {#sec0035}
==========

The complement system mediates host defence against pathogens, the elimination of immune complexes and apoptotic cells, and it facilitates adaptive immune responses ([@bib0140]). There is good evidence that complement activation is important in the pathogenesis of AMD (see accompanying review, [@bib0070]). Drusen, the hallmark lesion of early AMD, contain proteins from the alternative complement pathway including CFH, C3 and its activation products, and terminal pathway components including C5 and the membrane attack complex (MAC) ([@bib0095; @bib0005]). Patients with AMD have elevated levels of complement activation products in their circulation ([@bib0110; @bib0105; @bib0050]).

Complement activation is controlled by a large number of soluble and membrane bound regulatory proteins ([@bib0150]). CFH is the most important fluid phase regulator, present at high concentration in the plasma and body fluids and a key regulator of the alternative complement pathway. There is conclusive evidence that the common expressed variant Y402H (rs1061170) in the CFH gene influences susceptibility to AMD ([@bib0085; @bib0045; @bib0030]) with heterozygotes and homozygotes for the 402H allele being 2.5 and 6 times more likely to have AMD respectively ([@bib0130]). Other CFH variants are independently associated with AMD ([@bib0090]). A deletion of the neighbouring CFHR3 and CFHR1 genes has been shown to be protective for AMD ([@bib0055]) and these proteins are also involved in complement regulation. CFI is a cofactor with CFH for the inactivation of C3b and SNPs at the CFI locus also show an association with AMD ([@bib0035]). In the present study, we investigated the fluid phase protein, complement factor P (properdin). CFP is a stabilising component of the alternative pathway convertases and can bind to cells and pathogens, promoting convertase assembly and targeted phagocytosis ([@bib0065]). We found no evidence of an association between the SNPs typed in CFP and AMD. A recently published study of genetic variants in CFP from Finland was also negative ([@bib0115]).

Cell surfaces are also protected from complement activation by membrane bound proteins and we have investigated SNPs in the genes encoding three of these for association with AMD: CD46 (membrane cofactor protein, MCP), CD55 (decay accelerating factor, DAF) and CD59 (protectin). CD46 acts as cofactor for CFI mediated cleavage of C3b ([@bib0075]). CD55 inhibits the formation and accelerates the decay of C3 and C5 convertases ([@bib0075]). CD59 prevents final assembly of the MAC ([@bib0080]). We found no evidence of association with the SNPs typed in any of these genes. However, based on the confidence intervals for our odds ratios there is still the possibility that an association might exist up to a maximum OR of 1.8 in the case of rs7060246, and more generally in a range between 0.5 and 1.5 for other SNPs. Moreover, we cannot exclude the possibility of association with a common variant in poor LD with the SNPs typed, or indeed a rare variant that influences susceptibility to AMD.

We have studied these four complement pathway genes in a large well phenotyped case--control sample. The subjects used in the study were all examined by an ophthalmologist and had independent grading of their fundus photographs to confirm their disease status. This same sample has been used in other studies of AMD susceptibility and shows the expected associations with CFH, CFB/C2 and C3 ([@bib0120; @bib0145]). The absence of association with SNPs in CFP, CD46, CD55 and CD59 suggests that these are not important susceptibility genes for AMD.
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###### 

Disease status, sex, age and smoking history of subjects.[a](#tblfn0005){ref-type="table-fn"}

                                                                        Core sample      Enlarged sample                    
  --------------------------------------------------------------------- ---------------- ----------------- ---------------- ----------------
  Number of subjects                                                    262              446               359              622
  Disease status                                                                                                            
   Age-related maculopathy (ARM)                                                         19                                 26
   Geographic atrophy (GA)                                                               88                                 126
   Choroidal neovascularisation (CNV)                                                    267                                373
   Both GA and CNV                                                                       72                                 97
  Sex                                                                                                                       
   Male                                                                 105 (40%)        207 (46%)         146 (41%)        283 (46%)
   Female                                                               157 (60%)        239 (54%)         213 (59%)        339 (54%)
  Age                                                                                                                       
   Mean age, years (SD)                                                 **75.7 (7.8)**   **80.4 (6.8)**    **75.1 (7.9)**   **79.4 (7.1)**
  Pack years of cigarette smoking[b](#tblfn0010){ref-type="table-fn"}                                                       
   0                                                                    **106 (41%)**    **169 (38%)**     **150 (42%)**    **230 (37%)**
   0.1--20                                                              **103 (39%)**    **127 (29%)**     **133 (37%)**    **175 (28%)**
   20.1--40                                                             **39 (15%)**     **99 (22%)**      **56 (15%)**     **137 (22%)**
   \>40                                                                 **14 (5%)**      **51 (11%)**      **20 (6%)**      **79 (13%)**

Significant differences (at *p*-value ≤ 0.05) between cases and controls are reported in bold.

Information on smoking was missing for 1 case in the enlarged sample.

###### 

Association results for the 20 SNPs in the four complement regulator genes.

  Gene         SNP          Minor allele (a)   Major allele (A)   Genotype counts[a](#tblfn0015){ref-type="table-fn"} (aa/Aa/AA)   Minor allele frequency   OR     95% CI   *p*-value[b](#tblfn0020){ref-type="table-fn"}              
  ------------ ------------ ------------------ ------------------ ---------------------------------------------------------------- ------------------------ ------ -------- ----------------------------------------------- ---------- ------
  CFP          rs909523     T                  G                  18/89/129                                                        13/58/81                 0.27   0.25     1.1                                             0.8--1.4   0.73
               rs7060246    T                  C                  1/30/204                                                         1/19/137                 0.08   0.07     1.1                                             0.7--1.8   0.95
                                                                                                                                                                                                                                       
  CD46 (MCP)   rs2796267    G                  A                  97/205/144                                                       43/139/80                0.45   0.43     1.1                                             0.9--1.3   0.52
               rs2724385    T                  A                  99/224/115                                                       63/120/74                0.48   0.48     1.0                                             0.8--1.3   0.91
               rs2796269    T                  C                  55/188/200                                                       32/109/119               0.34   0.33     1.0                                             0.8--1.3   0.89
               rs2724374    C                  A                  15/166/259                                                       12/104/145               0.22   0.25     0.9                                             0.7--1.1   0.31
               rs3109808    C                  A                  70/231/142                                                       48/127/84                0.42   0.43     1.0                                             0.8--1.2   0.66
               rs6657476    T                  G                  15/166/263                                                       12/105/143               0.22   0.25     0.9                                             0.7--1.1   0.22
               rs7144       G                  A                  69/230/144                                                       46/132/83                0.42   0.43     0.9                                             0.8--1.2   0.60
                                                                                                                                                                                                                                       
  CD55 (DAF)   rs4844591    G                  A                  55/178/195                                                       25/112/120               0.34   0.32     1.1                                             0.9--1.4   0.43
               rs7544288    A                  G                  104/272/243                                                      66/168/124               0.39   0.42     0.9                                             0.7--1.1   0.19
                                                                                                                                                                                                                                       
  CD59         rs1047581    C                  T                  39/189/203                                                       28/94/121                0.31   0.31     1.0                                             0.8--1.3   0.97
               rs7046       A                  G                  61/195/161                                                       37/103/110               0.38   0.35     1.1                                             0.9--1.4   0.35
               rs17760306   G                  T                  14/105/307                                                       8/67/174                 0.16   0.17     0.9                                             0.7--1.2   0.62
               rs831631     C                  G                  66/210/163                                                       39/102/114               0.39   0.35     1.2                                             0.9--1.5   0.18
               rs12272807   T                  C                  2/72/371                                                         2/52/205                 0.09   0.11     0.8                                             0.5--1.1   0.15
               rs1738548    C                  T                  47/179/203                                                       28/100/123               0.32   0.31     1.0                                             0.8--1.3   0.78
               rs2231454    A                  G                  3/88/528                                                         5/59/294                 0.08   0.10     0.8                                             0.6--1.1   0.12
               rs3181274    A                  G                  61/193/175                                                       37/106/107               0.37   0.36     1.0                                             0.8--1.3   0.80
               rs17760694   C                  T                  16/131/291                                                       14/83/163                0.19   0.21     0.8                                             0.6--1.1   0.22

SNPs were genotyped in 446 cases and 262 controls. rs7544288 and rs2231454 were typed in the enlarged sample of 622 cases and 359 controls.

*p*-value for the Cochran--Armitage trend test.
